CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study GroupNorbert Schmitz, Michael Pfreundschuh, Samira Zeynalova et al.|Annals of Oncology|2011Cited by 105
CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)Norbert Schmitz, Michael Pfreundschuh, Samira Zeynalova et al.|Blood|2010Cited by 6
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid LeukemiaChristina Rautenberg, M. Middeke, Friedrich Stölzel et al.|Blood|2021Cited by 3
Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry ExperienceJulius C. Enßle, Björn Steffen, Sebastian Wolf et al.|Blood|2021Cited by 1
Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival BenefitMaher Hanoun, Christoph Röllig, Leo Ruhnke et al.|Blood|2021Cited by 0